Merck & Co., Inc. (MRK) Initiates Phase 3 Study Of Letermovir, An Investigational Antiviral For Prevention Of Cytomegalovirus (CMV) Infection In High-Risk Bone Marrow Transplant Patients
7/24/2014 10:54:55 AM
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir (MK-8228), an investigational antiviral agent. The multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of letermovir for the prevention of clinically-significant cytomegalovirus (CMV) infection in adult (18 years and older) CMV-seropositive recipients of allogeneic hematopoietic stem cell transplants.
Help employers find you! Check out all the jobs and post your resume.
comments powered by